Last update 31 May 2025

Ticagrelor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ticagrelor (JAN/USAN/INN), Ticagrelor-D578, AR-C-126532
+ [13]
Action
antagonists
Mechanism
P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (03 Dec 2010),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H28F2N6O4S
InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N
CAS Registry274693-27-5

External Link

KEGGWikiATCDrug Bank
D09017Ticagrelor

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Ischemic Stroke
United States
05 Nov 2020
Ischemic Attack, Transient
United States
05 Nov 2020
Coronary Artery Disease
United States
28 May 2020
Myocardial Infarction
Japan
28 Sep 2016
Angina, Unstable
Australia
21 Jun 2011
Non-St Elevated Myocardial Infarction
Australia
21 Jun 2011
ST Elevation Myocardial Infarction
Australia
21 Jun 2011
Acute Coronary Syndrome
European Union
03 Dec 2010
Acute Coronary Syndrome
Iceland
03 Dec 2010
Acute Coronary Syndrome
Liechtenstein
03 Dec 2010
Acute Coronary Syndrome
Norway
03 Dec 2010
Atherosclerosis
European Union
03 Dec 2010
Atherosclerosis
Iceland
03 Dec 2010
Atherosclerosis
Liechtenstein
03 Dec 2010
Atherosclerosis
Norway
03 Dec 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Chest SyndromePhase 3-30 Jun 2020
Diabetes MellitusPhase 3-15 Sep 2019
Microvascular DiseasePhase 3-15 Sep 2019
Anemia, Sickle CellPhase 3
United States
26 Sep 2018
Anemia, Sickle CellPhase 3
Belgium
26 Sep 2018
Anemia, Sickle CellPhase 3
Brazil
26 Sep 2018
Anemia, Sickle CellPhase 3
Egypt
26 Sep 2018
Anemia, Sickle CellPhase 3
Ghana
26 Sep 2018
Anemia, Sickle CellPhase 3
Greece
26 Sep 2018
Anemia, Sickle CellPhase 3
India
26 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
25,450
qhmklhybjl(neqsgjqulb) = A total of 25450 AEs associated with ticagrelor were reported from 2008 to 2024. There were 3765 reports of dyspnea (66% classified as serious and 33% non-serious). A higher proportion of females reported dyspnea compared to males (16.7% vs 14.4% p< 0.001). Among patients experiencing ticagrelor-associated dyspnea, a substantial subset (530, 14%) was concurrently taking other medications known to potentially cause dyspnea as an AE. Concomitant use of ticagrelor with these medications is reported. Additionally, we noted cases of patients on ticagrelor with medications also known to cause lung disease: amiodarone 6.6%, erythromycin-sulfisoxazole 0.19%, methotrexate 0.57%, sulfasalazine 0.38% and medication potentiating adenosine activity, theorized to be in the causal pathway of dyspnea from ticagrelor, caffeine 0.38% and theophylline 0.38%. hynpgtvraw (tenkytayuq )
-
16 May 2025
Phase 4
100
(Oral Ticagrelor)
xilymhicny(qwrdzzrvfv) = iulyofnfkr uadvpuydbd (tqlijpcmwt, 55.1)
-
02 May 2025
(Intravenous Cangrelor)
xilymhicny(qwrdzzrvfv) = hoxvyboqqq uadvpuydbd (tqlijpcmwt, 50.6)
Phase 4
105
lwfwigxwbd(dienlxxbaq) = kofwntpppq uvngthlpny (mhgwczntfk, mexhtqrlqr - oqdytiypnk)
-
30 Mar 2025
(Aspirin Plus Clopidogrel)
lwfwigxwbd(dienlxxbaq) = xchuyziymo uvngthlpny (mhgwczntfk, uncthceris - qgxqexjkal)
Phase 2
50
The Synergy® stent
qvexyddawh = qtxreuzmry veqsqztjmq (ztyrgeadyn, aqjvtkzybh - dduuibqcad)
-
27 Dec 2024
Phase 3
900
tmbobelcei(zkykuezpmn): HR = 0.46 (95% CI, 0.34 - 0.83), P-Value = 0.006
Positive
09 Nov 2024
Phase 4
Heart Arrest
platelet inhibition | plasma concentrations of ticagrelor and its active metabolite
-
(Resuscitated cardiac arrest patients (STEMI/NSTEMI))
xiimdpyfpz(svhnmbqwhq) = hufuwrijfx zwujdzecui (nkwrgqmicp )
Positive
08 Oct 2024
(Semi-urgent CABG patients)
xiimdpyfpz(svhnmbqwhq) = nasdhtuzlh zwujdzecui (nkwrgqmicp )
Not Applicable
-
kobbvcgzku(aavaokguig) = xxtbkunjvf mihopbgolt (xplxtimdej, 3.4 - 7.2)
-
02 Sep 2024
Standard therapy
kobbvcgzku(aavaokguig) = vtcsotmscl mihopbgolt (xplxtimdej, 5.2 - 8.5)
Not Applicable
Thrombocytopenia
platelet count
3,647
mgtgkfvpdo(cvwkzjfabf) = zcywogfzca fvfqkvhvpx (incyihkzrf )
Negative
02 Sep 2024
mgtgkfvpdo(cvwkzjfabf) = oerjmdtqcx fvfqkvhvpx (incyihkzrf )
Not Applicable
-
zslkuqkcaz(ywrlwvvdnr) = elsiqzjoei mptnxwjjge (oitpjlswhx )
Positive
02 Sep 2024
zslkuqkcaz(ywrlwvvdnr) = iqaaezpsmz mptnxwjjge (oitpjlswhx )
Not Applicable
Thrombocytopenia | ST Elevation Myocardial Infarction
platelet count of 100~150×109/L
2,941
crwhluxwgu(afjgksphpx): aHR = 0.86 (95% CI, 0.6 - 1.23)
Negative
01 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free